Dihydroartemisinin + PiperaquineThird Party Manufacturing in India

Dihydroartemisinin + Piperaquine is a WHO-recommended artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria. The two components work through distinct but complementary mechanisms against the malaria parasite.

Dihydroartemisinin is the active metabolite of artesunate and artemether. It contains an endoperoxide bridge that is essential for its antimalarial activity. When the malaria parasite digests hemoglobin inside its food vacuole, free heme is released. The ferrous iron in heme cleaves the endoperoxide bridge of dihydroartemisinin, generating cytotoxic carbon-centered free radicals. These free radicals alkylate and damage essential parasite proteins, lipids, and heme, leading to oxidative stress, proteasomal stress, and DNA damage. Dihydroartemisinin kills all intraerythrocytic stages of the parasite, particularly the ring stages and gametocytes, providing rapid parasite clearance and reducing transmission potential.

Piperaquine is a bisquinoline compound structurally related to chloroquine. It accumulates in the parasite's digestive vacuole and inhibits heme detoxification by preventing the polymerization of toxic free heme into inert hemozoin. This results in accumulation of toxic heme that destroys the parasite's cellular membranes. Piperaquine has a very long elimination half-life of approximately 20 to 22 days, providing prolonged post-treatment prophylaxis against reinfection.

The complementary pharmacokinetic profiles of dihydroartemisinin with its short half-life and rapid action and piperaquine with its long half-life and sustained effect allow a convenient three-day treatment regimen while minimizing the risk of resistance development.

Therapeutic Uses

Dihydroartemisinin + Piperaquine is indicated for the treatment of:

• Uncomplicated Plasmodium falciparum Malaria: As a first-line treatment recommended by the WHO. The combination provides rapid parasite clearance and high cure rates in both adults and children.
• Chloroquine-Resistant Malaria: Particularly effective in regions where P. falciparum has developed resistance to chloroquine and other conventional antimalarials. Dihydroartemisinin rapidly clears the majority of the parasite biomass, while piperaquine eliminates the remaining parasites.
• Mixed Malaria Infections: For treatment of mixed Plasmodium infections where P. falciparum is present alongside other species.
• Malaria in Endemic Regions: Used extensively in national malaria control programs across Southeast Asia, Africa, and the Western Pacific region where malaria is endemic.
• Pediatric Malaria: Available in child-friendly dosage strengths including 16mg+160mg and 32mg+320mg tablets for age-weighted dosing in pediatric populations.

Why Manufacturers Choose Dihydroartemisinin + Piperaquine

Dihydroartemisinin + Piperaquine is one of the six WHO-recommended artemisinin-based combination therapies and is included in the WHO Essential Medicines List. It offers a valuable manufacturing opportunity given the sustained global demand for ACTs, with major procurement by UN agencies, national malaria control programs, and international NGOs. Indian manufacturers are among the largest global producers of ACTs, serving tender-based supply to African and Southeast Asian markets. The combination requires specialized manufacturing expertise for the artemisinin component, which is sourced primarily from China and Vietnam. Indian WHO-GMP certified facilities with antimalarial product lines can competitively manufacture this combination for both institutional tender supply and private market distribution across malaria-endemic regions.